In this study, we showed that the hepatic Zbtb18 could activates FXR transcription, and subsequently accelerates the hepatic FAO, thereby preventing the onset and development of NAFLD. The gene discussed is ZBTB18; the disease is metabolic dysfunction-associated steatotic liver disease.